BioPharmSignal logoBioPharmSignal

Biotech News

Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

Candel Therapeutics (CADL)Candel TherapeuticsConference / presentation

Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer (NSCLC), and for linoserpaturev in recurrent glioblastoma PrTK05 data show systemic cytotoxic T-cell

Related news

CADLCandel Therapeutics2026-10-29 13:00 EST

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

CADLCandel Therapeutics2026-09-30 12:30 EST

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

MMSIMerit Medical2026-11-05 14:25 EST

Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

SNDXSyndax Pharmaceuticals2026-11-04 14:00 EST

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

View all latest news

Candel Therapeutics

Multimodal Cancer Immunotherapy Candel Therapeutics develops locally administered viral immunotherapies intended to induce immunogenic tumor-cell death and a systemic antitumor immune response. Aglatimagene Besadenovec Aglatimagene is an off-the-shelf, replication-defective adenovirus that delivers the HSV-thymidine-kinase gene into...

Recent company news

CADLCandel Therapeutics2026-11-06 14:00 EST

Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

CADLCandel Therapeutics2026-11-05 21:06 EST

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CADLCandel Therapeutics2026-11-02 21:05 EST

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CADLCandel Therapeutics2026-10-29 13:00 EST

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

CADLCandel Therapeutics2026-10-27 12:05 EST

Candel Therapeutics to Present at November Investor Conferences

Stock data

Close
8.04 USD
Market cap
616.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States